Group 1 - The company has received feedback from its internal rectification team confirming that the current trial progress is below expectations, and its subsidiary Tianjin Weiming is expected to be unable to resume normal production and operations within three months [1][2] - As a result of the above situation, the company's stock will be subject to "other risk warnings," changing its name from "Weiming Pharmaceutical" to "ST Weiming," with the stock code remaining "002581" and the daily price fluctuation limit changing from 10% to 5% [1][2] - The suspension of production and sales by Tianjin Weiming, which is a significant subsidiary responsible for the production and sales of interferon drugs, has a substantial impact on the company's operations, accounting for 60.09% of the company's revenue and 9.8% of the consolidated net profit [1][2] Group 2 - The company's board of directors acknowledges the adverse effects of the situation and plans to take effective measures to mitigate the impact, including promoting product sales in other markets and increasing efforts in market development and new product development [2] - Other subsidiaries of the company are operating normally and maintaining production capabilities, while the company aims to optimize management, reduce expenses, control costs, and enhance business profitability to ensure stable operations [3] - During the period of other risk warnings, the company will accept investor inquiries through phone and email, ensuring timely responses while adhering to insider information confidentiality regulations [3]

Core Viewpoint - Unimed Pharmaceutical's subsidiary, Tianjin Unimed, has been suspended from production and sales due to regulatory measures, significantly impacting the company's operations and revenue potential [2][3]. Group 1: Company Operations - Tianjin Unimed, primarily engaged in the production and sales of interferon drugs, generated revenue of 217 million yuan in 2024, accounting for 60.09% of Unimed Pharmaceutical's total revenue [2]. - The company's interferon business achieved revenue of 303 million yuan in 2023, representing 70.47% of total revenue, an increase from approximately 229 million yuan in 2022, which was 64.27% of total revenue [3]. - The main products contributing to Unimed's revenue are nerve growth factor and interferon products, which together account for over 90% of total revenue, with both categories having a gross margin close to 80% [2]. Group 2: Regulatory Issues - The suspension of Tianjin Unimed's production and sales is due to the interferon α2b spray being found non-compliant with biological activity standards, leading to procurement suspensions in multiple regions [2]. - The company must complete rectification and inspection to resume production, and products must meet national standards before being sold again [3]. - If the suspension lasts longer than three months, it may trigger additional risk warnings for the company [2].

Core Viewpoint - Unimed Pharmaceutical has reported a significant loss, with its major subsidiary, Tianjin Unimed Biopharmaceutical Co., Ltd., contributing 60% of its revenue, now facing production suspension due to regulatory issues [1][2]. Group 1: Company Performance - Unimed Pharmaceutical's stock price dropped to 7.42 yuan, a decrease of 9.95%, resulting in a market capitalization of 4.895 billion yuan following the announcement of the subsidiary's production halt [3]. - Tianjin Unimed's revenue for 2024 was 217 million yuan, with a net profit loss of 14 million yuan, highlighting its critical role in Unimed's overall financial performance [2][5]. - The company's interferon α2b spray, a key product, has been suspended from procurement by multiple regions due to quality issues, further impacting revenue [4][5]. Group 2: Regulatory and Operational Challenges - The Tianjin Municipal Drug Administration has mandated a production and sales suspension for Tianjin Unimed, requiring the completion of rectification and inspection before resuming operations [1][3]. - Unimed Pharmaceutical has initiated a self-inspection process following a quality control failure reported by the Shanghai Drug Administration, which found that a batch of the interferon α2b spray did not meet biological activity standards [4][5]. - If Tianjin Unimed cannot resume production within three months, Unimed Pharmaceutical may face additional risk warnings under the Shenzhen Stock Exchange regulations [2]. Group 3: Financial Implications - The interferon business accounted for 79.52%, 70.56%, and 60.09% of Unimed's revenue from 2022 to 2024, indicating its diminishing but still significant contribution to the company's financial health [5]. - Despite the high gross margin of 79.92% for the interferon products in 2024, Unimed has struggled with profitability, reporting a historical loss of 332 million yuan in 2023 [5].